Objects related with this person

What can we expect from myeloid growth factors?

Haemopoietic growth factors: unravelling the secrets of blood formation.

Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.

Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo.

Clinical use of haematopoietic growth factors.

Clinical use of growth factors.

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: five years on.

Haemopoietic growth factors: uses and misuses.

The importance of dose: lymphomas as a model of chemosensitive malignancies.

Filgrastim (r-metHuG-CSF): the first 10 years.

A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC.

Is cancer really a 'local' cellular clonal disease?



Related people:
K Welte
A Howell
J Chang
H Ludwig
L M Souza
S B Lucas
B I Lord
D Crowther
P M Wilkinson
G Martinelli
W Lange
R Mertelsmann
L Souza
M Lind
S Owens
N G Testa
R Stout
G Morgenstern
R Zittoun
T M Dexter
N Thatcher
R Willemze
M R Potter
J M Margison
J H Scarffe
A Gratwohl
N K Alton
T J de Witte
G Morstyn
M S Aapro
W P Steward
M J Lind
J Crown
H Zwierzina
P Hopwood
J Gabrilove
E Platzer
M H Bronchud
V Nuessler
M J Bargetzi
A J Croockewit
M J Blasco
M R Ranson
A G Kamthan